Interview with Peter van Tilburg, General Director / President, Cambridge Major…
It has now been 12 years since you co-founded ChemShop. One of the busiest, but probably most exciting moments in that period must have been the merger with CML in…
Address: Cambridge Major Laboratories Europe, B.V., Peelterbaan 2, 6002 NK Weert, Industrial area “De Kempen”, the Netherlands
Tel: ++31 (0)495 549 072
Web: http://www.c-mlabs.com/faceu.html
Cambridge Major Laboratories provides advanced chemistry services to the worlds leading pharmaceutical and biotechnology companies. We boast an impeccable reputation for delivering some of the most challenging projects and meeting the tightest timelines. And Cambridge Major’s reach is truly global in nature, operating four facilities in the US and Europe, serving hundreds of companies across the world.
Our philosophy revolves around strong R&D. With almost 50% of our scientists holding a Ph.D., Cambridge Major is well positioned to deliver on the most challenging and complex chemistry projects. Strong R&D to support early scale up during pre-clinical development will ensure that your molecule will transition into first-in-human studies as smoothly as possible. And we have the resources to provide all of your clinical and commercial API needs.
So when you are looking for a trusted partner to help take your molecule from concept to clinic and beyond, look to Cambridge Major. WE DELIVER.
The Weert facility (formerly ChemShop BV) is a 12,500 square meter site specializing in medicinal chemistry, process development, scale-up, clinical supplies, and low volume commercial supply of API’s. The facility houses fully isolated pilot suites with reactors of up to 1000 liter, and is fully GMP and ISO14001 certified. The facility has a wide range of capabilities including plant scale cryogenics (-100C) and high temperature (300C), high pressure reactions and high vacuum distillations.
It has now been 12 years since you co-founded ChemShop. One of the busiest, but probably most exciting moments in that period must have been the merger with CML in…
Bert de Jong, General Manager Benelux at Genzyme, discusses the solutions Genzyme is offering to patients suffering from rare diseases and MS in the Benelux and how these treatments add value overall…
Roche Netherlands General Manager Bart Vanhauwere explains how the company has managed to foster growth at the Dutch affiliate thanks to its long-term strategic vision and the collaborative approach it…
Europe’s longest-standing Minister of Health, Edith Schippers, provides insight into the local healthcare system and continued efforts to improve quality of life for Dutch citizens, as well as revealing the…
Sean Connor, General Manager Benelux and UK/ROI for ALK, details the company’s strategy both in terms of products and therapeutic areas and provides us with his assessment of Netherlands regulatory…
A well-established player in the Allergy market, the Dutch company HAL Allergy recently expanded its activities with the addition of its HALIX Contract Manufacturing Outsourcing (CMO) arm. CEO Harry Flore…
With almost thirty years of experience in the life sciences sector, local Dutch consultancy firm Baggerman Farma Consult offers a wide portfolio of services to its clients in the pharmaceutical…
Professor Paul Smits, Dean and Vice Chairman of Radboud University Medical Center in the Netherlands, shares his insights into the strengths of the country’s research climate and the challenges posed…
John Verhoeven, Partner and co-founder of Eagle Rock Life Sciences, a Dutch independent consultancy offering a broad range of services to both Dutch and international life sciences companies, explains how…
As Director of the Netherlands’ association for innovative medicines, Gerard Schouw outlines new strategies to enhance the Dutch research climate; foster greater collaboration between all stakeholders and improve public perception…
Manfred Rüdiger (MR), Robbert Van Heekeren (RVH) and Jeroen Rovers (JR), respectively CEO, CFO and CMO of Kiadis Pharma, a Dutch biopharmaceutical company focused on cell-based immunotherapy products for the…
After a successful IPO on Nasdaq in May 2015, Galapagos is ready to continue developing its robust portfolio of clinical-stage breakthrough therapies with the potential to revolutionize existing treatment paradigms.…
The future of drug development is about interacting, sharing and collaborating. The President and CEO of Genmab, an international biotechnology company focusing on differentiated antibody therapeutics for the treatment of…
See our Cookie Privacy Policy Here
